Share Name Share Symbol Market Type Share ISIN Share Description
Cyprotex Plc LSE:CRX London Ordinary Share GB00BP25RZ14 ORD £0.01
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 143.50p 142.00p 145.00p 143.50p 143.50p 143.50p 3,000 07:35:38
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 15.6 -6.5 -29.0 - 32.24

Cyprotex (CRX) Latest News

More Cyprotex News
Cyprotex Takeover Rumours

Cyprotex (CRX) Share Charts

1 Year Cyprotex Chart

1 Year Cyprotex Chart

1 Month Cyprotex Chart

1 Month Cyprotex Chart

Intraday Cyprotex Chart

Intraday Cyprotex Chart

Cyprotex (CRX) Discussions and Chat

Cyprotex Forums and Chat

Date Time Title Posts
13/9/201608:46Cyprotex ADME and Biosciences.79
02/8/201608:02Cyprotex ''Now the world's largest ADMETox specialist CRO''3,003
10/2/201511:31CRX - good times ahead2,933
04/6/201409:07Cyprotex - a buywell dud - dont touch it8
19/1/201119:57Cyprotex - 20081,876

Add a New Thread

Cyprotex (CRX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
28/09/2016 12:13:07144.003,0004,320.00O
View all Cyprotex trades in real-time

Cyprotex (CRX) Top Chat Posts

DateSubject
28/9/2016
09:20
Cyprotex Daily Update: Cyprotex Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker CRX. The last closing price for Cyprotex was 143.50p.
Cyprotex Plc has a 4 week average price of 146.53p and a 12 week average price of 139.48p.
The 1 year high share price is 155p while the 1 year low share price is currently 64p.
There are currently 22,468,340 shares in issue and the average daily traded volume is 7,295 shares. The market capitalisation of Cyprotex Plc is £32,242,067.90.
21/7/2016
10:14
rrb: agreed on dilution. Then the best thing for us all is the share price stays depressed until late 2018. I would expect interim results to show strong revenue and profitability growth but the non-cash hit due to share price.
13/6/2016
09:13
rrb: This purchase of the flow cytometry machine for biologics is actually a very smart move given immuno-oncology is one of hottest areas of medical research at the moment.... Yes, agreed with Husbod - no takeover but a 'technical' reason that triggered a strategic review. CLN issue will continue to keep share price around this level....unless CLN holders negotiate a mutually beneficial restructuring.
10/5/2016
07:43
rrb: the loan note will stop share price from rocketing. That said, someone made a good point about the tax rebate from the note, which offsets a decent chunk of the interest. We are looking at >£20m in revenues by next year. Given the operational gearing, this thing should be trading at multiples of current market price.
02/4/2016
08:49
buywell2: ....... Reasons to be Cheerful ( Part 3 ) .......... Firstly the AGM has to take place because of:- Section 656 of the Companies Act 2006 requires a public limited company whose net assets have fallen to half or less than half the amount of its called up share capital to call a general meeting to consider whether any, and if so what, steps should be taken to deal with the situation. Secondly , from the above: what steps should be taken to deal with the situation ? such steps could be a sale(whole)/part sale(ie Cyprotex UK or Cyprotex US ) /merger/strategic partnership deal/re-financing arrangement(getting rid of loan notes) to name but a few All avenues need to be explored to find the 'best value for shareholders' The company is obligated to undertake such actions and is doing it by means of a 'strategic review' Producing the results that Cyprotex has produced , with a depressed valuation in terms of the turnover, profits , cash in the bank, and improved trading due in no small part to a much improved website, has made Cyprotex an attractive target for a larger predator. Financial Highlights -- Strong revenue growth up 34.9% to GBP15.61 million (2014: GBP11.57 million) -- Gross margins increased to 77.3% (2014: 75.0%) -- Operating profit of GBP1.98 million, (2014: Operating loss, excluding goodwill impairment, of GBP0.71 million) -- Underlying EBITDA^ of GBP3.40 million (2014: GBP0.61 million) -- Cash generated from operations of GBP3.48 million (2014: used in operations GBP1.32 million) -- Underlying basic earnings^^ per share of 6.94 pence (2014: loss 19.67 pence) -- Cash of GBP5.4 million as at 31 December 2015 (2014: GBP2.9 million) Even more so with a decent outlook regarding trading prospects for 2016. Cyprotex can't stop a predator from coming along with an offer , for all we know one or more may be sniffing around as I key. I would be surprised and somewhat disappointed if they were not as in normal circumstances Cyprotex should have a market valuation of an average of 2 X its turnover and 20 X its profits. Which would be circa £35M instead of £22.5M ie the share price should be over 50% higher than it is or OVER 150P (ignoring the loan notes) In other words Cyprotex is a SCREAMING BUY at the current depressed share price. What I can't argue with however, is that IF Cyprotex improves turnover in 2016 by say 15%, less than half of the increase in 2015 , 2016 Turnover goes up to £17m and profits should come in at around £3M due to the exceptional margins of 77% that Cyprotex operates at. The market value would then be an average of 2 X 17M together with 20 X £3M Which would be £47M nearly 40% higher just 1 year later It is that 20 X profit aspect of the formula that makes ALL the difference. Which means TURNOVER has to grow in order to get it WITHOUT spending too much money Hence my addition to the thread header regarding a strategic partnership with Source BioScience , where Harwood Capital is also the main Institutional holder of shares. It is my belief that if done correctly with a simple selected targeted approach to achieve maximum benefits for both companies at minimum costs on a 50/50 basis The turnover of both and hence profits of both would increase in the first year of implementation and then grow in the second and third years. Now comes the interesting bit : Both Cyprotex and SourceBioScience service the MAJORITY of the WORLDS TOP TEN PHARMAS Both Cyprotex and SourceBioScience are specialists and excellent at what they do. The expertise is such that many of the TOP 10 WORLD's PHARMAS collaborate with them because Cyprotex and SourceBioScience have the technical nous, the IP, the assays , the predictive computer models, molecular diagnostics and testing, staff, labs , and equipment that RIVAL or in some cases exceed their own. And these are multi $ BILLION comanies But would any TOP 10 WORLD PHARMA ever buy Cyprotex or SourceBioScience ? NO .... not yet ... because they are too small in terms of Turnover and Profits An absolute minimum Turnover of £50M plus ($100M would be better) and profits of £5M ($10M would be better) would be needed before any one of the TOP 10 would make a bid. Source BioScience expect to turnover £30M in 2016 (£26.5M in 2015, profits should come in at about £3M (£2M in 2015) Like I have just outlined above Cyprotex should turnover around £17M in 2016 with profits of around £3M It will take a minimum of 5 years for either company to turnover £50M BUT If both companies form a strategic partnership their combined turnover should exceed £50M and profits exceed £5M WITHIN 12 MONTHS of such an announcement. This would be based if there was a combined increase of just 7% on expected numbers due to strategic partnership benefits in the first year after its commencement. BIG Cap companies pay DOUBLE the current share price if they want something , by BIG Cap I don't just mean the TOP 10 Pharmas I include the middle tier Pharmas as well as many Life Sciences Businesses. Hence the potential UPSIDE increases as well as the number of potential predators IF TURNOVER AND PROFITS fit the investment requirements under which such bigger companies operate. Get it ? ....... hTTps://www.youtube.com/watch?v=qcjh1a9Yoao ..... Nice one Ian
01/4/2016
19:58
buywell2: bahiflyer Welcome to the thread Thank-you for your views and I hope to see you posting some more along with some other advfn newbes that might get attracted as things hot up. Regarding the AGM Section 656 of the Companies Act 2006 requires a public limited company whose net assets have fallen to half or less than half the amount of its called up share capital to call a general meeting to consider whether any, and if so what, steps should be taken to deal with the situation. That big spike to 130p plus forced the AGM call However re the loan note debate and it is something that has got lots of folks panties in a bunch , has for some time , and must be very uncomfortable by now. The crux of the matter as I see it , keeping it simples , is ... The value of the embedded derivatives(loan notes) is linked to the company's share price. It may increase or decrease in line with share price movements until 30 September 2018 and is ultimately dependent on the share price of the company in the 30 days preceding 30 September 2018.
01/4/2016
19:26
bahiflyer: The loan notes do cloud the issue somewhat and I can understand why people would rather have them out the way for clarity. But unless you particularly need to see a short term share price increase then there are some accounting advantages to keeping them in place and not just for future tax losses. The company assumes that both redeemable and convertible notes will be redeemed for cash and therefore the derivative which is taken as a finance cost is the total number of notes multiplied by the increase in share price from 60p. This makes up the increase finance cost mostly of the £8.5M, which is accounted for as a loss. Two things about that apart from carrying future tax losses. Firstly all current operational profit is offset by the loss so remains with the company, building a reasonable bank cash balance for which we gain interest. Its like we're building up cash to eventually pay off the redeemables and its being partly funded by the tax man because all profits remain with the company. Secondly I would expect the majority of CLNs will be converted for shares, not redeemed for cash. But we are assuming all loans will be redeemed for cash in the accounts yet most of that cash element will never leave the company if CLNs are converted into shares at maturity. Its quite clever really and not too easy to get your head around, or to explain for that matter.
31/3/2016
16:47
buywell3: I am pleased to see that Cyprotex are now a specialist ADME-Tox and BioScience Contract Research Organization (CRO) as the late arriving RNS today says. The growth of the new BioSciences Division is important V the march of personalized medicine 3D assays using human cells are the way to go The EPA seems to like them from what I have read , so perhaps some more work from that direction. The Hurel Corporation is also in the same game hTTp://www.prweb.com/releases/2016/03/prweb13262792.htm Perhaps Cyprotex can beat them on price and/or delivery ? Don't forget Cyprotex still has a Toxicology contract with the EPA ToxCast program with around $10M to still be spent by 2018 It is good to see Cyprotex keeping ahead of the CRO pack in its innovative use of new technology , together with the employment of creative and knowledgeable staff that put such technology to best use for the industries that Cyprotex services. The recent drift in Share Price should I feel be clawed back when the finals get released. The EPA sure has a lot of Toxicology testing to arrange The recent successful legal challenges made by companies previously granted 'Conditional Approval' by the EPA and then subsequently unsuccessfully withdrawn by the EPA after such chemicals had been found to cause harm to various crustaceans,other water life and invertebrates: were made based upon 'computational modelled programs ' for toxicological data outcomes. It would seem that the EPA will have to add 3D In-Vitro Toxicology assays to the In-Silico predictive data in order to win a court judgement. Cyprotex PLC Launch of Advanced 3D Liver Model 31/03/2016 9:58am Launch of Advanced 3D Liver Model Cyprotex PLC (AIM:CRX; www.cyprotex.com), a specialist ADME-Tox and Bioscience Contract Research Organisation (CRO), today announces the launch of an advanced 3D liver model for detecting hepatotoxic potential. Hepatotoxicity is a major cause of drug attrition and preclinical animal studies often fail to detect this type of drug-induced toxicity. As a result, in some cases, hepatotoxic liability is only detected at a late stage when the drug has reached the clinic. In vitro-based human cellular models are showing promise as alternatives to animal based testing and are able to provide a mechanistic understanding of hepatotoxicity. These cellular models may be performed in either 2D (e.g., cell suspensions or monolayers attached to the bottom of plates) or 3D (e.g., scaffold/support-based or scaffold-free microtissues/spheroids) format. 3D models have advantages over 2D cellular models in the fact that they have improved cell to cell contact and communication, and are amenable to longer term cultures enabling extended repeat dose studies to be replicated. Furthermore, functional drug metabolising activity is observed within the 3D microtissues over extended time periods which may be important for drugs exerting their adverse effects through the formation of a toxic metabolite in the liver. Cyprotex has specialist expertise in 3D cellular research and has developed various organ specific models (such as liver, heart, brain and kidney models) and co-culture models (where more than one cell type is incorporated in the model). Through Cyprotex's investment in confocal high content analysis equipment for imaging, a detailed analysis of the 3D cellular structures can be performed. Cyprotex's new 3D hepatotoxicity model analyses multiple high content endpoints enabling an accurate prediction of the likelihood of liver toxicity in humans, and allowing the mechanism behind the hepatotoxicity to be explored in detail. Dr Anthony Baxter, Cyprotex's Chief Executive Officer, comments on the introduction of the new 3D technology: "Developing 3D cell-based models has been a key focus of our research during the past 12 months. Not only are these models proving valuable for toxicology testing but they are also showing promise in efficacy and ADME testing, and are being used within a number of different industries. For example, in vitro reconstructed 3D skin models are now the standard technique within the cosmetics market for testing skin and ocular irritation and corrosion. Although 2D models are currently the preferred choice for testing new pharmaceuticals, this is expected to change as the potential of 3D technology is realised."
19/11/2015
22:57
buywell3: buywell2 has mentioned 30M several times in recent years Another decent contract win might do the trick ... perhaps a government one ? Is Cyprotex plc a Buy? The Stock Gapped Up Today November 16, 2015 · The stock of Cyprotex plc (LON:CRX) gapped up by GBX 0.747 today and has GBX 229.38 target or 176.00% above today’s GBX 83.11 share price. The 6 months technical chart setup indicates low risk for the GBX 18.39 million company. The gap was reported on Nov, 17 by Barchart.com. If the GBX 229.38 price target is reached, the company will be worth GBX 32.37M more. Gaps up are useful for using as a support level and to some extent as a tradeable event. If investors already hold the stock and experience a price gap up, then its usually a good idea to hold the stock for a stronger up move. Back-tests of these patterns indicate that two-thirds of the times the stock performance improves after the gap. The area gaps close 89% of the time, the breakaway gaps, 2%, the continuation gaps 4% and the exhaustion gaps 61%. The stock increased 3.89% or GBX 3.11 on November 16, hitting GBX 83.11. About 72,681 shares traded hands or 320.41% up from the average. Cyprotex plc (LON:CRX) has risen 50.00% since April 20, 2015 and is uptrending. It has outperformed by 53.47% the S&P500. After Today’s Huge Increase, Is Cyprotex plc’s Near-Term Analysis Positive? November 17, 2015 The stock of Cyprotex plc (LON:CRX) is a huge mover today! The stock is down 1.06% or GBX 0.89 after the news, hitting GBX 83.11 per share. Cyprotex plc (LON:CRX) has risen 50.00% since April 20, 2015 and is uptrending. It has outperformed by 52.54% the S&P500. The move comes after 9 months positive chart setup for the GBX 17.97M company. It was reported on Nov, 17 by Barchart.com. We have GBX 159.57 PT which if reached, will make LON:CRX worth GBX 16.53M more.
03/11/2015
08:52
rico1234: I don't understand the massive positive feelings here, and maybe someone can explain because I don't understand it correctly. At maturity date CRX needs to pay back £5.1m on the loans and the total number of shares will increase with 27.5%. The money was supposedly for take-overs that would make more money than the cost of the loans. So far, everybody happy. But, so far CRX has just burned this cash without doing any significant take-overs. Last year EPS was negative, this year, despite the upbeat trading statement, we're still expecting to make a loss. Come 2018, CRX share price will fall sharply, or CRX will have not enough money to pay back the loans (and everyone will be forced to take a share conversion, which leads to a dilution of 60%+). Where am I wrong?
03/7/2014
17:23
buywell2: I have decided to step back and post less ..... the future of Cyprotex like you guys have said rests now with the BIG Institutions that have taken a big holding in Cyprotex and others that will join as turnover increases and EPA contracts start to kick in. The ones like us that have been in for years will now hopefully be taken onwards and upwards by them. Comments re a USA listing made today by a few of you are valid. I have posted before that as Cyprotex USA grows by acquisitions , and I hope soon to read of another, a NASDAQ listing to access USA Investors who place a HIGHER value on Pharma Biotechs than their UK counterparts do ..... makes sound business sense. The NOMAD Singer N+1 has recently advised Xenetic BioSciences was (XEN on AIM ) now XBIO on the OTC USA exchange to go down this route. They de-listed from AIM and did a deal with a small USA existing OTC listed company to get listed and then changed the company name. By share consolodations their price has been hovering around the $1 mark and they hope to get listed on NASDAQ by Xmas this year. So it can be done, and I think the NOMAD has had some input in this regard as they did with Xenetic (same NOMAD) .... also as I have said before , same NOMAD as Source BioScience (SBS) where incidently Oryx Growth Fund recently bought a 3.2% stake. hTTp://www.bullbearings.co.uk/traders.views.php?gid=1&id=635 My gut feeling is within 24 months Cyprotex could be in a position to list on NASDAQ IF they still wanted to do so. I do not think they would go for a DUAL listing , Xenetic didn't , and the NOMAD advice will I believe remain the same. There are some strings however to think on......but if turnover is kept on the rise these should not be a problem. However they are: The number one reason for companies that have received de-listing notices from the Nasdaq Markets is: Failure to comply with the Nasdaq's minimum bid price requirement. So, what is this requirement? How does it come into effect? What can the company do about it? What is the requirement? The minimum bid price requirement stems from Section 5550(a)(2) of the Nasdaq's Equity Rules guide. It clearly states: "(a) Continued Listing Requirements for Primary Equity Securities: (2) Minimum bid price of at least $1 per share." How does it come into effect? If a company closes below a $1/share bid price for 30 consecutive days, the Nasdaq sends the company a written notice. The notice states that the company is no longer in compliance with its continued listing requirements and has 180 days to regain compliance. Otherwise, the company will face delisting. What can the company do about non-compliance? As stated above, the company has 180 calendar days to regain compliance. In that time frame, if the company closes at or above a $1/share bid price for ten consecutive days, the Nasdaq will inform the company that it has regained compliance, and close the issue. So, the matter then becomes raising the share price (every stock's ultimate goal). There are a few ways a company can do this: 1.Good performance: Good financial performance is perhaps the most pure way to raise a stock's price. After all, better financials increase the company's value and thus its shares' value. This, however, is difficult and can take time; too much time in some cases. Good performance is also the hardest way to increase share price. 2.Good press: The saying goes, "any press is good press." Why? Press drives interest. When a company makes news, people notice. Issuing press releases on what the company is doing can send investors a company's way. Increased buyers result in increased volume, which can drive share price up. 3.Reverse split: We have discussed this topic time and time again. While this would most certainly raise a company's share price, it is a zero-sum transaction. That means the company's value is the same. For example, a company with 10 million shares at $0.50/share has a $5 million market cap. To regain compliance, the company enacts a 2 for 1 reverse split. The result is 5 million shares worth $1.00 each. The company is still worth just $5 million. 4.Buybacks: We have discussed this quite a bit too. When a company buys back shares, it decreases the number outstanding, increasing the value of those left. Ideally, this raises a company's price per share. However, the company must have the capital to purchase shares. If raising share price was simple, every stock would be an easy pick. However, it's not that simple. A company has to work to up its value. It has to work much harder to regain compliance if its share price has fallen below $1/share. Investors should watch companies not meeting this requirement extra close. Why are they not meeting the requirement? Often times, poor share performance is a direct reflection of poor company performance. So, find out what is going on to drive the company's stock below the $1 mark. To the investor, the underlying issue is more important than the minimum bid requirement. Although, if a company is delisted, it's visibility could drop significantly–a story for another day. Bonne Chance Mes Amis
Cyprotex share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:32 V: D:20160929 05:04:42